NATCO Pharma Limited – FDA 483, Oct 18, 2023
NATCO Pharma Limited, an Indian manufacturer of sterile and non-sterile drug products, was cited for significant deficiencies during an FDA inspection. Observations included inadequate cleaning and maintenance of equipment leading to potential cross-contamination, and a lack of proper quality control unit oversight regarding GMP documentation and data integrity. The firm also failed to establish adequate procedures to prevent microbiological contamination in sterile drug products and had deficiencies in OOS investigations and computer system controls.
ID · 10dc5409-7a8f-438a-84ec-a39ae77c0ab3
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.